Composition
- Active ingredients
- CABAZITAXEL 60MG/1.5ML (40MG/ML)
Strengths and forms
The FDA lists each strength of a product separately; these pages share one label.
- CABAZITAXEL 60MG/1.5ML (40MG/ML) · SolutionANDA207619-001 · Discontinued
- CABAZITAXEL UNKNOWN · UnknownANDA207735-001 · Tentative approval
- CABAZITAXEL 60MG/6ML (10MG/ML) · SolutionNDA207970-001 · Discontinued
- CABAZITAXEL 60MG/1.5ML (40MG/ML) · SolutionANDA207693-001 · Prescription
- CABAZITAXEL 20MG/ML · InjectableNDA207937-001 · Tentative approval
- CABAZITAXEL 60MG/1.5ML (40MG/ML) · SolutionThis page
- CABAZITAXEL 60MG/1.5ML (40MG/ML) · SolutionANDA207736-001 · Discontinued
- CABAZITAXEL 60MG/6ML (10MG/ML) · SolutionNDA208715-002 · Tentative approval
- CABAZITAXEL 45MG/4.5ML (10MG/ML) · SolutionNDA208715-001 · Tentative approval
- CABAZITAXEL 60MG/1.5ML (40MG/ML) · SolutionANDA207381-001 · Discontinued
- CABAZITAXEL 60MG/3ML (20MG/ML) · SolutionNDA207949-001 · Discontinued
Official product information
Drugs@FDA lists the approved labels, letters and reviews for application ANDA207718.
At a glance
- Brand name
- Cabazitaxel
- Route
- Intravenous
- Dosage form
- Solution
- Applicant
- DR Reddys
- Status
- Prescription
- FDA approval
- 10 Feb 2023
- Application
- ANDA207718-001